iSpecimen Inc. (ISPC): Total Liabilities
$6.44M
As of 2025-12-31
$5.66M
As of 2026-06-30
+14.4%
3-year compound annual growth
-22.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.44M | +6.7% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $6.04M | -0.6% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $6.08M | +41.1% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $4.31M | -27.3% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $5.93M | -73.4% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $22.31M | n/a | 2022-03-22, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.44M | +6.7% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $5.12M | -74.0% |
| Absci Corp (ABSI) | 2025-12-31 | $26.85M | -22.1% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $3.68M | -5.8% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $1.20M | +5.2% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $33.50M | -8.1% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $33.89M | -10.7% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
Compare ISPC, ONMD, ABSI, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗